Lifetime Citizen Portal Access — AI Briefings, Alerts & Unlimited Follows
Senate committee backs bill letting pharmacists order certain at‑home vaccines, citing FDA approval as safety guard
Loading...
Summary
The Finance Committee voted to report favorably a bill allowing pharmacists to order vaccines for at‑home administration (including by an adult caregiver) when the vaccine is FDA‑approved for self‑administration; members debated scope, caregiver definition and liability before voting to advance the bill.
The Senate Finance Committee on March 5 voted to report favorably a bill that would allow a pharmacist to order a vaccine for someone age 3 or older to be administered at home rather than requiring the pharmacist to give the shot in a clinic or pharmacy.
Committee staff said the change would let a pharmacist order an FDA‑approved vaccine for home administration and requires a pharmacist who orders a vaccine to inform the patient or adult caregiver about the importance of pediatric primary care and to refer when appropriate. The staff noted FluMist, the nasal‑mist influenza vaccine, is currently the only vaccine approved for this type of at‑home administration.
Members asked whether the bill effectively allows any vaccine to be mailed to a consumer. "The addition…does not specify the method of administration. It is left entirely to the method approved by the FDA," staff said, arguing that FDA approval would be the practical limit on what could be shipped for at‑home use. Senator William explained the practical example to other members: FluMist is a nasal spray with an established safety profile and could be shipped and self‑administered or administered by a parent for a minor.
Other members asked whether 'caregiver' is defined in statute; staff said the term is already used in current law governing pharmacist‑administered vaccinations and appears in relevant regulations. Concerns about liability and adverse reactions were raised and answered by a reminder that vaccine adverse events can be pursued through the federal Vaccine Injury Compensation Program.
After discussion the committee voted to report the bill favorably. Members who pressed for limitation to a nasal spray were told that limiting the bill to a single mode of administration could unintentionally preclude future FDA‑approved self‑administered vaccines.
The measure will move from committee with a favorable report; staff and members said they expect FDA approval and federal guidance to shape how the provision is applied in practice.
